ストックスクリーナーアプリを入手
0.394
0.93%
-0.0037
アフターアワーズ：
.39
-0.004
-1.02%
Mereo Biopharma Group Plc Adr (MREO) 最新ニュース
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Mereo BioPharma Group plcSponsored ADR $MREO Stock Holdings Raised by Aberdeen Group plc - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - ChartMill
Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - marketscreener.com
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - Finviz
Mereo BioPharma Faces Securities Litigation - Intellectia AI
MREO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
Mereo BioPharma Group plc Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsMREO - ChartMill
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
MREO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Mereo BioPharma Group plc - Barchart.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma - Chartmill
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Mereo BioPharma Group plc Securities Class Action Lawsuit - Chartmill
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Hold” by Brokerages - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - ChartMill
MREO Stock Price, Forecast & Analysis | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - Chartmill
Mereo BioPharma Group’s (MREO) “Buy” Rating Reiterated at BTIG Research - Defense World
A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update - Sahm
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift - Sahm
MREO: Setrusumab delivers robust BMD and pain improvements in OI, with key regulatory steps ahead - TradingView — Track All Markets
Mereo BioPharma Group (NASDAQ:MREO) Given New $3.00 Price Target at Needham & Company LLC - Defense World
MREO: Late-stage rare disease pipeline advances with strong data, strategic partnerships, and solid cash runway - TradingView — Track All Markets
Mereo BioPharma updates setrusumab program, extends cash runway - Investing.com
Mereo BioPharma updates setrusumab program, extends cash runway By Investing.com - Investing.com India
Mereo BioPharma Provides Corporate Update - Investing News Network
10 Stocks Under $1 That Will Explode - Insider Monkey
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
1.52%
1.68%
大文字化:
|
ボリューム (24 時間):